AAAAAA

   
Results: 1-10 |
Results: 10
DIFFERENTIAL TRACE AMINE ALTERATIONS IN INDIVIDUALS RECEIVING ACETYLENIC INHIBITORS OF MAO-A (CLORGYLINE) OR MAO-B (SELEGILINE AND PARGYLINE)
Authors: MURPHY DL KAROUM F PICKAR D COHEN RM LIPPER S MELLOW AM TARIOT PN SUNDERLAND T
Citation: Dl. Murphy et al., DIFFERENTIAL TRACE AMINE ALTERATIONS IN INDIVIDUALS RECEIVING ACETYLENIC INHIBITORS OF MAO-A (CLORGYLINE) OR MAO-B (SELEGILINE AND PARGYLINE), Journal of neural transmission. Supplementum, (52), 1998, pp. 39-48
BEHAVIORAL-EFFECTS OF KETAMINE CANNOT BE EXPLAINED BY CINGULATE ACTIVATION
Authors: HEIDEBRINK JL MINOSHIMA S GIORDANI B MELLOW AM JOHANNS JR LITTLE RJA FOSTER NL
Citation: Jl. Heidebrink et al., BEHAVIORAL-EFFECTS OF KETAMINE CANNOT BE EXPLAINED BY CINGULATE ACTIVATION, Annals of neurology, 42(3), 1997, pp. 41-41
PHENOBARBITAL DOES NOT REDUCE THE ADVERSE-EFFECTS OF LOW-DOSE KETAMINE
Authors: HEIDEBRINK JL GIORDANI B MELLOW AM JOHANNS JR LITTLE RJA FOSTER NL
Citation: Jl. Heidebrink et al., PHENOBARBITAL DOES NOT REDUCE THE ADVERSE-EFFECTS OF LOW-DOSE KETAMINE, Annals of neurology, 42(3), 1997, pp. 42-42
COGNITIVE, BEHAVIORAL, AND MOTOR EFFECTS OF THE NMDA ANTAGONIST KETAMINE IN HUNTINGTONS-DISEASE
Authors: MURMAN DL GIORDANI B MELLOW AM JOHANNS JR LITTLE RJA HARIHARAN M FOSTER NL
Citation: Dl. Murman et al., COGNITIVE, BEHAVIORAL, AND MOTOR EFFECTS OF THE NMDA ANTAGONIST KETAMINE IN HUNTINGTONS-DISEASE, Neurology, 49(1), 1997, pp. 153-161
MANAGEMENT OF TREATMENT RESISTANCE IN THE DEPRESSED GERIATRIC-PATIENT
Authors: KAMHOLZ BA MELLOW AM
Citation: Ba. Kamholz et Am. Mellow, MANAGEMENT OF TREATMENT RESISTANCE IN THE DEPRESSED GERIATRIC-PATIENT, The Psychiatric clinics of North America, 19(2), 1996, pp. 269
COGNITIVE, BEHAVIORAL, AND MOTOR EFFECTS OF THE NMDA ANTAGONIST KETAMINE IN HUNTINGTONS-DISEASE
Authors: MURMAN DL GIORDANI B MELLOW AM JOHANNS JR LITTLE RJA FOSTER NL
Citation: Dl. Murman et al., COGNITIVE, BEHAVIORAL, AND MOTOR EFFECTS OF THE NMDA ANTAGONIST KETAMINE IN HUNTINGTONS-DISEASE, Neurology, 45(4), 1995, pp. 253-253
HIGH-DOSE SELEGILINE IN TREATMENT-RESISTANT OLDER DEPRESSIVE PATIENTS
Authors: SUNDERLAND T COHEN RM MOLCHAN S LAWLOR BA MELLOW AM NEWHOUSE PA TARIOT PN MUELLER EA MURPHY DL
Citation: T. Sunderland et al., HIGH-DOSE SELEGILINE IN TREATMENT-RESISTANT OLDER DEPRESSIVE PATIENTS, Archives of general psychiatry, 51(8), 1994, pp. 607-615
CSF SOMATOSTATIN IN ALZHEIMERS-DISEASE AND MAJOR DEPRESSION - RELATIONSHIP TO HYPOTHALAMIC-PITUITARY-ADRENAL AXIS AND CLINICAL MEASURES
Authors: MOLCHAN SE HILL JL MARTINEZ RA LAWLOR BA MELLOW AM RUBINOW DR BISSETTE G NEMEROFF CB SUNDERLAND T
Citation: Se. Molchan et al., CSF SOMATOSTATIN IN ALZHEIMERS-DISEASE AND MAJOR DEPRESSION - RELATIONSHIP TO HYPOTHALAMIC-PITUITARY-ADRENAL AXIS AND CLINICAL MEASURES, Psychoneuroendocrinology, 18(7), 1993, pp. 509-519
A PEPTIDE ENHANCEMENT STRATEGY IN ALZHEIMERS-DISEASE - PILOT-STUDY WITH TRH-PHYSOSTIGMINE INFUSIONS
Authors: MELLOW AM ARONSON SM GIORDANI B BERENT S
Citation: Am. Mellow et al., A PEPTIDE ENHANCEMENT STRATEGY IN ALZHEIMERS-DISEASE - PILOT-STUDY WITH TRH-PHYSOSTIGMINE INFUSIONS, Biological psychiatry, 34(4), 1993, pp. 271-273
BEHAVIORAL-EFFECTS OF THE NMDA ANTAGONIST, KETAMINE, IN ALZHEIMERS-DISEASE
Authors: MELLOW AM FOSTER NL ARONSON SM GIORDANI B STLAURENT RT BERENT S
Citation: Am. Mellow et al., BEHAVIORAL-EFFECTS OF THE NMDA ANTAGONIST, KETAMINE, IN ALZHEIMERS-DISEASE, Biological psychiatry, 33(6A), 1993, pp. 142-142
Risultati: 1-10 |